Date: 23 Jan 2013
On Growth Option for R&D Continuity of Biotech Start-ups Under Uncertainty
- Takao Fujiwara
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
For biotech drug-discovery start-ups, even though the constraint on managerial resources is very severe, it takes more than 10 years for them to transfer a project from laboratory study to products on the market. In order to increase robustness against financial crisis for continuing R&D, we examine the flexibility value of real options, and especially pay attention to the function of growth options for business entry and exit. Through a case study of a Japanese pioneering start-up in the field of regenerative medicine, J-TEC, we consider a survival strategy during the valley of deficit from the perspective of the growth option. Finally, we apply stochastic optimization to select the pipeline candidates from alternative projects.
Anderson, C., et al. (2006). Empirical evidence on capital investment, growth options, and security returns. Journal of Finance, 61(1), 171–194.
Berk, J., et al. (1999). Optimal investment, growth options, and security returns. Journal of Finance, 54(5), 1553–1607.
Black, F., et al. (1973). The pricing of options and corporate liabilities. Journal of Political Economy, 81(3), 637–654.
Brisley, N. (2006). Executive stock options: Early exercise provisions and risk-taking incentives. Journal of Finance, 61(5), 2487–2509.
Burrill and Company. (2009). Biotech 2009. San Francisco, CA: Burrill & Company LLC.
Burrill and Company. (2010). Biotech 2010. San Francisco, CA: Burrill & Company LLC.
Copeland, T., & Antikarov, V. (2001). Real Options: A practitioner’s guide. New York, NY: Texere.
Dixit, A. (1989). Entry and exit decisions under uncertainty. Journal of Political Economy, 97(3), 620–638.CrossRef
Dixit, A. K., & Pindyck, R. S. (1994). Investment under uncertainty. Princeton, NJ: Princeton University Press.
Fujiwara, T. (2008a). Japan’s health-care service quality and the death-valley strategy of biotech start-ups. Global Journal of Flexible Systems Management, 9(1), 1–10.
Fujiwara, T. (2008b). Modeling of strategic partnership of biotechnological start-up by option-game: Aiming at optimization between flexibility and commitment. Journal of Advances in Management Research, 5(1), 28–45.CrossRef
Fujiwara, T. (2010). Application of real options analysis for biotech-cluster formation: Optimal investment timing of biotech start-ups under uncertainty. In C. Jayachandran, et al. (Eds.), Business Clusters: Partnering for strategic advantage (pp. 193–215). New Delhi, India: Routledge.
Fujiwara, T. (2011). Application of timing option to founding investment decision of biotech start-ups. Journal of Business Chemistry, 8(3), 133–146.
J-TEC, the company home page. (2011). http://www.jpte.co.jp/english/ir/index.html. Accessed 31 Dec 2011.
Kester, W. C. (1984). Today’s options for tomorrow’s growth. Harvard Business Review, 62(March-April), 153–160.
Kulatilaka, N., & Trigeorgis, L. (1994). The general flexibility to switch: Real options revisited. International Journal of Finance, 6(2), 778–798.
Kulatilaka, N., et al. (1998). Strategic growth options. Management Science, 44(8), 1021–1031.
Merton, R.C. (1973). Theory of rational option pricing. Bell Journal of Economics and Management Science, 4(1), 141–183.
Mun, J. (2006). Modeling risk. Hoboken, NJ: Wiley.
Myers, S.C. (1974). Interactions of corporate financing investment decision: Implications for capital budgeting. Journal of Finance, 29(1), 1–25.
Nikkei.com home page. (2011). http://e.nikkei.com/e/fr/freetop.aspx. Accessed 31 Dec 2011.
Smit, H.T.J., et al. (2004). Strategic investment: Real options and games. Princeton, NJ: Princeton University Press.
Smith, R. L., et al. (2004). Entrepreneurial finance (2nd ed.). Hoboken, NJ: Wiley.
Timmons, J., et al. (2009). New venture creation, entrepreneurship for the 21st century (8th ed.). Boston, MA: McGraw-Hill/Irwin.
Trigeorgis, L. (1996). Real Options: Managerial flexibility and strategy in resource allocation (pp. 1–4). Cambridge, MA: MIT Press.
- On Growth Option for R&D Continuity of Biotech Start-ups Under Uncertainty
Global Journal of Flexible Systems Management
Volume 13, Issue 3 , pp 129-139
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Biotech start-ups
- Real options
- Growth options
- Valley of deficit
- Path dependent continuity
- Takao Fujiwara (1)
- Author Affiliations
- 1. Toyohashi University of Technology, Toyohashi, Aichi, 441-8580, Japan